AAPS and Springer Nature announce an exciting opportunity for an exceptional candidate to serve as Editor-in-Chief of the journal, *The AAPS Journal*.

*The AAPS Journal*, an official journal of the American Association of Pharmaceutical Scientists, is committed to publishing novel and impactful research that should be mechanism-based and hypothesis-driven, and addresses significant issues in drug discovery, development, and regulation.

Candidates should have a Ph.D., M.D., or equivalent degree, and comprehensive knowledge and understanding of drug discovery, development, and regulation. In addition, candidates should have a distinguished research and publication record, high standing among peers, and prior experience in peer-review activities related to the publication of research in drug discovery, development, and regulation. Experience as Editor-in-Chief or Associate Editor of a scientific peer-review journal is an asset.

Responsibilities include timely and objective review of manuscripts under consideration by the journal, closely collaborating with the publisher and AAPS to select Associate Editors and the Editorial Board, and commissioning submissions in areas of interest and scope. The Editor-in-Chief will work routinely with AAPS on journal development with the goal of furthering the journal’s impact and reach, and advancing the field of drug discovery, development, and regulation.

A full description of the responsibilities involved is appended to this announcement. The appointment will cover a renewable 3-year term and will include an editorial stipend and free registration to all meetings and workshops, including PharmSci 360 and NBC. During the term, the EiC must be an AAPS member.

Interested candidates should submit their curriculum vitae, three references, and publication and editorial records to AAPS’ Publication Manager, Matt Baughman at BaughmanM@aaps.org. Deadline for applications is **March 31, 2023**, or open until a suitable candidate has been found. Training will begin in the Fall of 2023, appointment officially starts on January 1, 2024.
Responsibilities:

a. Editor-in-Chief, working in consultation with Associate Editors or other Editors that may be appointed, shall exercise control of the editorial development and editorial content of the journal, and shall be responsible for applying consistently high editorial standards to all published contributions.

b. Editor-in-Chief shall be responsible for supplying Publisher with refereed and accepted manuscripts and other editorial material, prepared in accordance with the journal’s published guidelines to authors.

c. Editor-in-Chief is required to handle the submissions through the peer-review system in a timely manner. AAPS and Publisher will provide editorial office support.

d. Editor-in-Chief, in consultation with Publisher and AAPS, shall select highly qualified Editors and ensure international representation and diverse expertise.

e. Editor-in-Chief, in consultation with Associate Editors, shall make recommendations in the selection of an Editorial Board that provides both international representation and diverse expertise. Publisher and AAPS shall have the joint responsibility to appoint the Editorial Board Members.

f. Editor-in-Chief may select Guest Editors, who shall be responsible for soliciting and acquiring manuscripts for thematic issues of journal.

g. Editor-in-Chief shall use his/her best efforts to promote and to assist AAPS and the Publisher in promoting the journal at relevant meetings and within the appropriate scientific communities.

h. Editor-in-Chief adheres to standards of editorial good practice, as defined in the Publisher’s Code of Conduct for Editors-in-Chief.

i. Make reasonable business efforts to attend the annual PharmSci 360, and its associated business and editorial board and strategy meetings.